Novabridge Biosciences ADR (NBP)

$4.15 -0.02 (-0.48%)
Market Cap 480.66M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 320,700
Avg Vol 1,555,836
Day's Range N/A - N/A
Shares Out 115.27M
Stochastic %K 31%
Beta 1.45
Analysts Strong Sell
Price Target $8.60

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Latest News on NBP
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

Oct 29, 2025, 6:27 PM EDT - 16 days ago

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

Oct 29, 2025, 9:00 AM EDT - 16 days ago

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

Oct 22, 2025, 12:35 PM EDT - 23 days ago

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

Oct 17, 2025, 6:16 PM EDT - 4 weeks ago

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

Oct 16, 2025, 4:05 PM EDT - 4 weeks ago

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market

Sep 10, 2025, 5:05 PM EDT - 2 months ago

I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

Aug 25, 2025, 7:00 AM EDT - 2 months ago

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee

I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 3 months ago

I-Mab to Participate in September Investor Conferences

Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 3 months ago

Everest Medicines Expands Strategic Investment in I-MAB

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

Aug 1, 2025, 8:00 AM EDT - 3 months ago

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

Jul 17, 2025, 7:00 AM EDT - 4 months ago

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jul 2, 2025, 11:15 AM EDT - 4 months ago

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 30, 2025, 4:01 PM EDT - 4 months ago

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Jun 26, 2025, 6:30 AM EDT - 5 months ago

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 6 months ago

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 21, 2025, 4:30 PM EDT - 8 months ago

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 9 months ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

I-Mab to Participate in Leerink Partners Global Healthcare Conference

Feb 18, 2025, 7:00 AM EST - 9 months ago

I-Mab to Participate in Leerink Partners Global Healthcare Conference

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:30 AM EST - 10 months ago

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Jan 8, 2025, 7:00 AM EST - 11 months ago

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Jan 6, 2025, 7:00 AM EST - 11 months ago

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab to Participate at the Piper Sandler Healthcare Conference

Nov 21, 2024, 7:00 AM EST - 1 year ago

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

I-Mab Reports Third Quarter 2024 Results

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 1 year ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Participate at the Truist Securities BioPharma Symposium

Oct 28, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Sep 10, 2024, 7:00 AM EDT - 1 year ago

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 11:50 AM EDT - 1 year ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

Aug 28, 2024, 7:00 AM EDT - 1 year ago

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

Aug 7, 2024, 7:00 AM EDT - 1 year ago

I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)

I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

Jun 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

BMY

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

May 23, 2024, 5:05 PM EDT - 1 year ago

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the Jefferies Global Healthcare Conference

I-MAB Filed 2023 Annual Report on Form 20-F

Apr 30, 2024, 7:00 AM EDT - 1 year ago

I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Apr 5, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

Apr 2, 2024, 4:01 PM EDT - 1 year ago

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Reports Full Year 2023 Financial Results and Business Update

Mar 14, 2024, 5:00 PM EDT - 1 year ago

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options

Biotech firm I-Mab to divest China operations, shift focus to US

Feb 7, 2024, 8:36 AM EST - 1 year ago

Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Feb 7, 2024, 6:00 AM EST - 1 year ago

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Nov 6, 2023, 8:00 AM EST - 2 years ago

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023